Mechanisms of apoptosis in irradiated and sunitinib-treated follicular thyroid cancer cells

Apoptosis

Volumn 19, Issue 3, 2014, Pages 480-490

  Grosse, Jirka ^a   Warnke, Elisabeth ^b   Wehland, Markus ^b   Pietsch, Jessica ^b   Pohl, Fabian ^a   Wise, Petra ^c   Magnusson, Nils E ^d,e   Eilles, Christoph ^a   Grimm, Daniela ^b,e  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d AARHUS UNIVERSITY   (Denmark)

^e AARHUS UNIVERSITY   (Denmark)

Author keywords

Apoptosis; Caspases; Irradiation; Sunitinib; Survivin; Thyroid cancer

Indexed keywords

ADENOCARCINOMA, FOLLICULAR; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; CELL LINE, TUMOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; INDOLES; INHIBITOR OF APOPTOSIS PROTEINS; PROTEIN KINASE INHIBITORS; PYRROLES; THYROID NEOPLASMS;

EID: 84894457641     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-013-0937-0     Document Type: Article

References (65)

1. Thompson CB (1995) Apoptosis in the pathogenesis and treatment of disease. Science 267:1456-1462
2. Kossmehl P, Kurth E, Faramarzi S, Habighorst B, Shakibaei M, Wehland M, Kreutz R, Infanger M, J Danser AH, Grosse J, Paul M, Grimm D (2006) Mechanisms of apoptosis after ischemia and reperfusion: role of the renin-angiotensin system. Apoptosis 11:347-358
3. Schoenberger J, Bauer J, Moosbauer J, Eilles C, Grimm D (2008) Innovative strategies in in vivo apoptosis imaging. Curr Med Chem 15:187-194
4. Wong RS (2011) Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res 30:87
5. Kerr JF, Wyllie AH, Currie AR (1972) Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26:239-257
6. Ashkenazi A, Dixit VM (1998) Death receptors: signaling and modulation. Science 281:1305-1308
7. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y, Nagata S (1991) The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66:233-243
8. Yonehara S, Ishii A, Yonehara M (1989) A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 169:1747-1756
9. Nicholson DW, Thornberry NA (1997) Caspases: killer proteases. Trends Biochem Sci 22:299-306
10. Wang J, Lenardo MJ (1997) Molecules involved in cell death and peripheral tolerance. Curr Opin Immunol 9:818-825
11. Mooney LM, Al-Sakkaf KA, Brown BL, Dobson PR (2002) Apoptotic mechanisms in T47D and MCF-7 human breast cancer cells. Br J Cancer 87:909-917
12. Casciola-Rosen L, Nicholson DW, Chong T, Rowan KR, Thornberry NA, Miller DK, Rosen A (1996) Apopain/CPP32 cleaves proteins that are essential for cellular repair: a fundamental principle of apoptotic death. J Exp Med 183:1957-1964
13. Tsujimoto Y (1998) Role of Bcl-2 family proteins in apoptosis: apoptosomes or mitochondria? Genes Cells 3:697-707
14. Kondo T, Ezzat S, Asa SL (2006) Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6:292-306
15. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ (1995) Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 80:285-291
16. Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917-921
17. Kawasaki H, Toyoda M, Shinohara H, Okuda J, Watanabe I, Yamamoto T, Tanaka K, Tenjo T, Tanigawa N (2001) Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer 91:2026-2032
18. Ettl T, Stiegler C, Zeitler K, Agaimy A, Zenk J, Reichert TE, Gosau M, Kühnel T, Brockhoff G, Schwarz S (2012) EGFR, HER2, survivin, and loss of pSTAT3 characterize high-grade malignancy in salivary gland cancer with impact on prognosis. Hum Pathol 43:921-931
19. Fukuda S, Pelus LM (2006) Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther 5:1087-1098
20. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, Reed JC (1998) IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58:5315-5320
21. Shin S, Sung BJ, Cho YS, Kim HJ, Ha NC, Hwang JI, Chung CW, Jung YK, Oh BH (2001) An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochem 40:1117-1123
22. Liu T, Brouha B, Grossman D (2004) Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells. Oncogene 23:39-48
23. Altieri DC (2003) Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3:46-54
24. Andersen MH, Thor SP (2002) Survivin - a universal tumor antigen. Histol Histopathol 17:669-675
25. Ambrosini G, Adida C, Sirugo G, Altieri DC (1998) Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem 273:11177-11182
26. Sausville EA (2002) Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends Mol Med 8:S32-S37
27. Zaffaroni N, Pennati M, Colella G, Perego P, Supino R, Gatti L, Pilotti S, Zunino F, Daidone MG (2002) Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci 59:1406-1412
28. Rödel F, Hoffmann J, Distel L, Herrmann M, Noisternig T, Papadopoulos T, Sauer R, Rödel C (2005) Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 65:4881-4887
29. Agate L, Lorusso L, Elisei R (2012) New and old knowledge on differentiated thyroid cancer epidemiology and risk factors. J Endocrinol Invest 35:3-9
30. Nix P, Nicolaides A, Coatesworth AP (2005) Thyroid cancer review 2: management of differentiated thyroid cancers. Int J Clin Pract 59:1459-1463
31. Eustatia-Rutten CF, Corssmit EP, Biermasz NR, Pereira AM, Romijn JA, Smit JW (2006) Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab 91:313-319
32. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F, Schlumberger M (2006) Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91:2892-2899
33. Baudin E, Schlumberger M (2007) New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncol 8:148-156
34. SUTENT Summary of Product Characteristics (2012) Pfizer Limited, Kent, UK. http://www.medicines.org.uk/emc/medicine/18531/spc. Accessed 2 Oct 2013
35. Patyna S, Laird AD, Mendel DB, O'farrell AM, Liang C, Guan H, Vojkovsky T, Vasile S, Wang X, Chen J, Grazzini M, Yang CY, Haznedar JO, Sukbuntherng J, Zhong WZ, Cherrington JM, Hu-Lowe D (2006) SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Mol Cancer Ther 5:1774-1782
36. Chow LQ, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25:884-896
37. Willhauck MJ, Schott M, Kreissl MC, Fassnacht M, Spitzweg C (2011) Neue Therapieoptionen bei fortgeschrittenen Schilddrüsenkarzinomen. Dtsch Med Wochenschr 136:1165-1168
38. Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE, Martins RG (2010) Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 16:5260-5268
39. Schueneman AJ, Himmelfarb E, Geng L, Tan J, Donnelly E, Mendel D, McMahon G, Hallahan DE (2003) SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 63:4009-4016
40. Grosse J, Warnke E, Pohl F, Magnusson NE, Wehland M, Infanger M, Eilles C, Grimm D (2013) Impact of sunitinib on human thyroid cancer cells. Cell Physiol Biochem 32:154-170
41. Lin JD, Chao TC, Weng HF, Huang HS, Ho YS (1996) Establishment of xenografts and cell lines from well-differentiated human thyroid carcinoma. J Surg Oncol 63:112-118
42. Piscazzi A, Costantino E, Maddalena F, Natalicchio MI, Gerardi AM, Antonetti R, Cignarelli M, Landriscina M (2012) Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines. J Clin Endocrinol Metab 97:E898-E906
43. Pohl F, Hassel S, Nohe A, Flentje M, Knaus P, Sebald W, Koelbl O (2003) Radiation-induced suppression of the Bmp2 signal transduction pathway in the pluripotent mesenchymal cell line C2C12: an in vitro model for prevention of heterotopic ossification by radiotherapy. Radiat Res 159:345-350
44. Pohl F, Grosse J, Grimm D, Brockhoff G, Westphal K, Moosbauer J, Koelbl O, Infanger M, Eilles C, Schoenberger J (2010) Changes of apoptosis, p53, and bcl-2 by irradiation in poorly differentiated thyroid carcinoma cell lines: a prognostic marker for the prospect of therapeutic success? Thyroid 20:159-166
45. Grosse J, Grimm D, Westphal K, Ulbrich C, Moosbauer J, Pohl F, Koelbl O, Infanger M, Eilles C, Schoenberger J (2009) Radiolabeled annexin V for imaging apoptosis in radiated human follicular thyroid carcinomas - is an individualized protocol necessary? Nucl Med Biol 36:89-98
46. Tseng LM, Huang PI, Chen YR, Chen YC, Chou YC, Chen YW, Chang YL, Hsu HS, Lan YT, Chen KH, Chi CW, Chiou SH, Yang DM, Lee CH (2012) Targeting signal transducer and activator of transcription 3 pathway by cucurbitacin I diminishes self-renewing and radiochemoresistant abilities in thyroid cancer-derived CD133+cells. J Pharmacol Exp Ther 341:410-423
47. Infanger M, Faramarzi S, Grosse J, Kurth E, Ulbrich C, Bauer J, Wehland M, Kreutz R, Kossmehl P, Paul M, Grimm D (2007) Expression of vascular endothelial growth factor and receptor tyrosine kinases in cardiac ischemia/reperfusion injury. Cardiovasc Pathol 16:291-299
48. Magnusson NE, Dyrskjot L, Grimm D, Wehland M, Pietsch J, Rungby J (2012) Gene networks modified by sulphonylureas in beta cells: a pathway-based analysis of insulin secretion and cell death. Basic Clin Pharmacol Toxicol 111:254-261
49. Ma X, Wehland M, Aleshcheva G, Hauslage J, Waßer K, Hemmersbach R, Infanger M, Bauer J, Grimm D (2013) Interleukin-6 expression under gravitational stress due to vibration and hypergravity in follicular thyroid cancer cells. PLoS One 8:e68140
50. Grosse J, Wehland M, Pietsch J, Schulz H, Saar K, Hübner N, Eilles C, Bauer J, Abou-El-Ardat K, Baatout S, Ma X, Infanger M, Hemmersbach R, Grimm D (2012) Gravity-sensitive signaling drives 3-dimensional formation of multicellular thyroid cancer spheroids. FASEB J 26:5124-5140
51. Grosse J, Wehland M, Pietsch J, Ma X, Ulbrich C, Schulz H, Saar K, Hübner N, Hauslage J, Hemmersbach R, Braun M, van Loon J, Vagt N, Infanger M, Eilles C, Egli M, Richter P, Baltz T, Einspanier R, Sharbati S, Grimm D (2012) Short-term weightlessness produced by parabolic flight maneuvers altered gene expression patterns in human endothelial cells. FASEB J 26:639-655
52. Wehland M, Ma X, Braun M, Hauslage J, Hemmersbach R, Bauer J, Grosse J, Infanger M, Grimm D (2013) The impact of altered gravity and vibration on endothelial cells during a parabolic flight. Cell Physiol Biochem 31:432-451
53. Grimm D, Bauer J, Schoenberger J (2009) Blockade of neoangiogenesis, a new and promising technique to control the growth of malignant tumors and their metastases. Curr Vasc Pharmacol 7:347-357
54. Wehland M, Bauer J, Infanger M, Grimm D (2012) Target-based anti-angiogenic therapy in breast cancer. Curr Pharm Des 18:4244-4257
55. Pasqualetti G, Ricci S, Boni G, Tognini S, Polini A, Mariani G, Ferdeghini M, Monzani F (2012) Off-label use of sunitinib in patients with advanced, epithelial thyroid cancer: a retrospective analysis. Recent Pat Endocr Metab Immune Drug Discov 6:171-176
56. Grimm D, Wehland M, Pietsch J, Infanger M, Bauer J (2011) Drugs interfering with apoptosis in breast cancer. Curr Pharm Des 17:272-283
57. Kossmehl P, Shakibaei M, Cogoli A, Infanger M, Curcio F, Schönberger J, Eilles C, Bauer J, Pickenhahn H, Schulze-Tanzil G, Paul M, Grimm D (2003) Weightlessness induced apoptosis in normal thyroid cells and papillary thyroid carcinoma cells via extrinsic and intrinsic pathways. Endocrinology 144:4172-4179
58. Cory S, Huang DC, Adams JM (2003) The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 22:8590-8607
59. Yang F, Jove V, Xin H, Hedvat M, Van Meter TE, Yu H (2010) Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling pathways. Mol Cancer Res 8:35-45
60. Sonpavde G, Jian W, Liu H, Wu MF, Shen SS, Lerner SP (2009) Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol Oncol 27:391-399
61. Prevostel C, Alvaro V, Boisvilliers F, Martin A, Jaffol C, Joubert D (1995) The natural protein kinase C α mutant is present in human thyroid neoplasms. Oncogene 11:669-674
62. Wetsel WC, Khan WA, Merchenthaler I, Rivera H, Halpern AE, Phung HM, Negro-Vilar A, Hannun YA (1992) Tissue and cellular distribution of the extended family of protein kinase C isoenzymes. J Cell Biol 117:121-133
63. Yin Z, Pringle DR, Jones GN, Kelly KM, Kirschner LS (2011) Differential role of PKA catalytic subunits in mediating phenotypes caused by knockout of the Carney complex gene Prkar1a. Mol Endocrinol 25:1786-1793
64. Howie HL, Shiflett SL, So M (2008) Extracellular signal-regulated kinase activation by Neisseria gonorrhoeae downregulates epithelial cell proapoptotic proteins Bad and Bim. Infect Immun 76:2715-2721
65. Fenton MS, Marion KM, Salem AK, Hogen R, Naeim F, Hershman JM (2010) Sunitinib inhibits MEK/ERK and SAPK/JNK pathways and increases sodium/iodide symporter expression in papillary thyroid cancer. Thyroid 20:965-974